MRNA vs REGN Stock Comparison
REGN currently leads MRNA in this stock comparison, with AIQ scores of 68 vs 46. The clearest difference is quality.
What is the main difference between MRNA and REGN?
REGN leads the current stock comparison as Regeneron Pharmaceuticals, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Moderna, Inc. vs Regeneron Pharmaceuticals, Inc.
REGN leads
REGN leads by 22 AIQ points, primarily on Quality and Value, and the lead has widened from 1 points over 30 sessions.
Stable: 5 of 6 evidence groups support REGN, its lead is widening, and its signal state is cleanly positive.
Moderna, Inc.
Regeneron Pharmaceuticals, Inc.
The Algovestiq AIQ Score currently favors REGN over MRNA, 68 versus 46 as of Oct 21, 2026. REGN's advantage is driven primarily by stronger quality and value. REGN also shows the weaker technical structure relative to its 50-day moving average. 5 of 6 covered evidence groups favor REGN today, and the comparison is rated Stable on stability: the lead has swung materially session to session. REGN lead: Strengthening — the AIQ differential moved from 1 to 22 points over 30 sessions. REGN leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.
Compare Moderna, Inc. and Regeneron Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare MRNA and REGN against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality27 vs 73REGN +46
- Value34 vs 48REGN +14
- Momentum78 vs 91REGN +13
- Risk Resilience54 vs 60REGN +6
5 of 6 evidence groups favor REGN. REGN’s edge is concentrated in quality and value.
What changed since the last close
Latest scored session 2026-10-20, compared against the prior scored session 2026-10-19.
Largest factor move: Momentum +9
New signals
- BB Upper Band Breach — bearish, volatility, short horizon
Largest factor move: Momentum +17
New signals
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
REGN's lead widened by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — MRNA and REGN both carry a full feed there.
The central trade-off
REGN (Regeneron Pharmaceuticals, Inc.): the stronger current systematic profile, led by quality and value.
MRNA (Moderna, Inc.): the counter-case, on technicals — but at materially higher volatility, 87.1% against 31.2%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
REGNREGN on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
REGNREGN on combined revenue and EPS growth.
Value
REGNREGN on the peer-relative Value factor, by 14 points.
Momentum
REGNREGN on the Momentum factor, by 13 points.
Lower downside
REGNREGN on Risk Resilience, by 6 points.
Analyst upside
REGNREGN on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | MRNA | REGN | Note |
|---|---|---|---|
| Implied upside to target | -61.1% | +2.7% | REGN has more room |
| Target dispersion | +230.1% | +47% | Lower is tighter analyst agreement |
| Consensus | Hold | Buy | Context, not a primary driver |
| Analysts covering | 10 | 20 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor REGN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | REGN | 46 vs 68 |
| Fundamentals | REGN | revenue growth -62.7% vs 19%; EPS growth 42.4% vs 80.1%; TTM ROE -39.2% vs 13.8%; gross margin -12.6% vs 84.9%; operating margin -149% vs 25.6% |
| Valuation | REGN | Value 34 vs 48 |
| Technicals | MRNA | Price vs 50-day 51.8% vs 1.9%; vs 200-day 204.7% vs 9.8% |
| Risk Resilience | REGN | Risk Resilience 54 vs 60 |
| Analyst expectations | REGN | Target upside -61.1% vs 2.7% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of MRNA and REGN and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 22 points. (supports the conclusion holding)
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has swung materially session to session. (argues the conclusion is provisional)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on REGN.
How the comparison changed
120 daily snapshots · Jun 21 – Oct 20REGN lead: Strengthening — the AIQ differential moved from 1 to 22 points over 30 sessions.
- Today
- REGN +22
- 46 vs 68
- 7 sessions ago
- REGN +19
- 46 vs 65
- 30 sessions ago
- REGN +1
- 48 vs 49
- 90 sessions ago
- REGN +22
- 46 vs 68
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
5 bullish / 1 bearish / 1 neutral, conflicted
Only MRNA
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (7.39%)
- BB Upper Band Breach — bearish, volatility, short horizon
- 52-Week High Proximity — bullish, risk, long horizon (0.0%)
4 bullish / 0 bearish
No signal that the other name lacks.
Both carry 4 more signals that do not separate them: Golden Cross Active, EMA Ribbon Expansion Bullish, Uptrend Structure Active, MACD Bullish Crossover.
MRNA is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved up over the latest session (price +1.54%, AIQ +2 points).
Price is down while the AIQ Score moved up 4 points over the same session — price and model disagree (price -0.22%, AIQ +4 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1MRNA closes the Quality gap — currently 46 points behind, the largest single contributor to REGN's edge.
- 2MRNA's BB Upper Band Breach resolves — a bearish volatility rule currently active against it.
- 3REGN's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
REGN leads on balance| Metric | MRNA | REGN |
|---|---|---|
| Revenue growth (YoY) | -62.7% | 19% |
| EPS growth (YoY) | 42.4% | 80.1% |
| Gross margin | -12.6% | 84.9% |
| Operating margin | -149% | 25.6% |
| Return on equity (TTM) | -39.2% | 13.8% |
| Debt to equity | 0.19 | 0.06 |
Performance
MRNA leads 6 of 6 windows| Metric | MRNA | REGN |
|---|---|---|
| 1 week (5 sessions) | 11.9% | 7.2% |
| 1 month (20 sessions) | 32.6% | 0.4% |
| 3 months (63 sessions) | 280.9% | 24% |
| 6 months (126 sessions) | 334% | 8% |
| Year to date | 667% | 4.6% |
| 1 year (252 sessions) | 787.7% | 41.9% |
Technicals
MRNA has the stronger structure| Metric | MRNA | REGN |
|---|---|---|
| RSI (14) | 66.8 | 64.8 |
| ADX (14) | 61.9 | 18.8 |
| Price vs 50-day | 51.8% | 1.9% |
| Price vs 200-day | 204.7% | 9.8% |
| Volatility (1M, annualized) | 87.1% | 31.2% |
Risk
REGN is the more resilient| Metric | MRNA | REGN |
|---|---|---|
| Beta | 2.03 | 0.58 |
| Sharpe ratio | 1.69 | 1.05 |
| Sortino ratio | 6.82 | 1.7 |
| Max drawdown | -34.2% | -26.1% |
| Current drawdown | 0% | -5.2% |
| Annualized volatility | 193.8% | 33.5% |
| Value at risk (95%) | -6.9% | -2.7% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, MRNA or REGN?
On the Algovestiq AIQ Score, REGN is the stronger of the two as of Oct 21, 2026, scoring 68 against MRNA's 46. The edge comes from quality and value. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is MRNA or REGN the better buy right now?
REGN carries the stronger systematic profile as of Oct 21, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor REGN over MRNA?
The composite weights Quality, Value, Momentum and Risk Resilience. REGN leads Quality by 46 points; REGN leads Value by 14 points; REGN leads Momentum by 13 points. REGN leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by MRNA simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.
Which has more analyst upside, MRNA or REGN?
Analyst price targets imply -61.1% upside for MRNA and +2.7% for REGN, so the Street currently favors REGN. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, MRNA or REGN?
REGN is the better-valued of the two on the peer-relative Value factor. REGN on the peer-relative Value factor, by 14 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, MRNA or REGN?
REGN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, MRNA or REGN?
REGN on the Momentum factor, by 13 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, MRNA or REGN?
REGN is the more resilient of the two, so the other name carries the higher downside risk. REGN on Risk Resilience, by 6 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is MRNA more profitable than REGN?
REGN leads on the comparable margin measures — gross margin -12.6% vs 84.9%; operating margin -149% vs 25.6%; ttm roe -39.2% vs 13.8%.
Is REGN's lead over MRNA getting stronger or weaker?
REGN lead: Strengthening — the AIQ differential moved from 1 to 22 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-21 and 2026-10-20. The lead has not changed hands in that window.
What would change the MRNA vs REGN verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: MRNA closes the Quality gap — currently 46 points behind, the largest single contributor to REGN's edge; MRNA's BB Upper Band Breach resolves — a bearish volatility rule currently active against it; REGN's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about MRNA and REGN?
MRNA: 5 bullish / 1 bearish / 1 neutral, conflicted. REGN: 4 bullish / 0 bearish. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on MRNA is Golden Cross Active (bullish, long horizon). On REGN it is Golden Cross Active (bullish, long horizon).
Compare MRNA and REGN with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.